Verrica appoints Gavin Corcoran to board as Class I director

Verrica Pharmaceuticals Inc.

Dr. Corcoran appointed effective March 31, 2025; term expires at 2025 annual meeting.
Granted option to purchase 17,502 shares at grant-date closing price; vests over 3 years.
Receives $40,000 annual retainer; eligible for annual option of 20,000 shares.
Currently Chief Development Officer of Formation Bio; former CMO of Allergan and Actavis.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gavin Corcoran

Director

VRCA · Verrica Pharmaceuticals Inc.

Effective: 2025-03-31
Filed: April 2, 2025, 7:59 PM ET

On March 31, 2025, the Board of Directors (the “ Board ”) of Verrica Pharmaceuticals Inc. (the “ Company ”) appointed Gavin Corcoran to serve as a director of the Company effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gavin Corcoran was appointed as Director at Verrica Pharmaceuticals Inc..

Action: appointed
Role: Director

Exact text from the filing

On March 31, 2025, the Board of Directors (the “ Board ”) of Verrica Pharmaceuticals Inc. (the “ Company ”) appointed Gavin Corcoran to serve as a director of the Company effective immediately.

View on SEC.gov

Verrica Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-071389

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.